Skip to main content
. 2023 Mar 21;19(6):1861–1874. doi: 10.7150/ijbs.82567

Figure 6.

Figure 6

ALW-II-41-27 enhanced the in vivo effect of chemotherapy against BLBC tumors. (A) Measurement of changes in the size of the tumor in different groups of treatment in vivo after treatment with chemotherapeutic agents PTX (1 mg/kg) or DDP (1 mg/kg), alone or in combination with ALW-II-41-27 (1 mg/kg); (B) Display of tumor tissues removed at the endpoint of control or drug treatment (day 24); (C) Statistics for weight of all tumor tissues; (D) Body weight of nude mice in each group; (E) Schematic representation of the scientific hypothesis that the inflammatory factor TNF-α promotes BLBC cell stemness by activating KLF5-EphA2 axis expression and thereby promoting pS897 EphA2-mediated chemoresistance; EphA2 inhibitor ALW-II-41-27 inhibits BLBC cell stemness and enhances chemotherapeutic drug sensitivity of BLBC cells, indicating that the membrane protein EphA2 is a potential therapeutic target for BLBC. * or ns indicates the significance between Viechle group and other individual group, and # indicates the significance between single drug groups (PTX, DDP, or ALW) with combined-drugs groups (DDP+ALW, or PTX+ALW).